U.S. Viral Vectors and Plasmid DNA Manufacturing Market Size to Hit USD 11.69 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type,

7.1.1. Adenovirus

7.1.1.1. Market Revenue and Forecast

7.1.2. Plasmid DNA

7.1.2.1. Market Revenue and Forecast

7.1.3. Lentivirus

7.1.3.1. Market Revenue and Forecast

7.1.4. Retrovirus

7.1.4.1. Market Revenue and Forecast

7.1.5. AAV

7.1.5.1. Market Revenue and Forecast

7.1.6. Others

7.1.6.1. Market Revenue and Forecast

Chapter 8. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

8.1. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type,

8.1.1. Gene Therapy

8.1.1.1. Market Revenue and Forecast

8.1.2. Antisense &RNAi

8.1.2.1. Market Revenue and Forecast

8.1.3. Cell Therapy

8.1.3.1. Market Revenue and Forecast

8.1.4. Vaccinology

8.1.4.1. Market Revenue and Forecast

Chapter 9. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

9.1. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type,

9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)

9.1.1.1. Market Revenue and Forecast

9.1.2. Downstream Processing (Fill-finish, Purification)

9.1.2.1. Market Revenue and Forecast

Chapter 10. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type

10.1. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type,

10.1.1. Biopharmaceutical and Pharmaceutical Companies

10.1.1.1. Market Revenue and Forecast

10.1.2. Research Institutes

10.1.2.1. Market Revenue and Forecast

Chapter 11. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, By Disease

11.1. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease,

11.1.1. Genetic Disorders

11.1.1.1. Market Revenue and Forecast

11.1.2. Cancer

11.1.2.1. Market Revenue and Forecast

11.1.3. Infectious Diseases

11.1.3.1. Market Revenue and Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Forecast

Chapter 12. U.S. Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

12.1.6. U.S.

12.1.6.1. Market Revenue and Forecast, by Vector

12.1.6.2. Market Revenue and Forecast, by Application

12.1.6.3. Market Revenue and Forecast, by Workflow

12.1.6.4. Market Revenue and Forecast, by End-User

12.1.7. Market Revenue and Forecast, by Disease

Chapter 13. Company Profiles

13.1. Novasep

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Aldevron

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Merck Waisman Biomanufacturing

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Creative Biogene

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. The Cell and Gene Therapy Catapult

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Cobra Biologics

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. uniQure N.V.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Addgene

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. FUJIFILM Holdings Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Oxford Biomedicaplc

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

13.11. Takara Bio Inc.

13.11.1. Company Overview

13.11.2. Product Offerings

13.11.3. Financial Performance

13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The U.S. viral vectors and plasmid DNA manufacturing market size is expected to increase from USD 2.84 billion in 2025 to USD 11.69 billion by 2035.

Answer : The U.S. viral vectors and plasmid DNA manufacturing market is expected to grow at a compound annual growth rate (CAGR) of around 15.20% from 2026 to 2035.

Answer : The major players in the U.S. viral vectors and plasmid DNA manufacturing market include Andelyn Biosciences, BioReliance, Bluebird Bio, Brammer Bio, Catalent Cell & Gene Therapy, Catalent Viral Vector Manufacturing, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Lonza Houston, Novartis Gene Therapies, Oxford Biomedica Solutions, Resilience, Sarepta Therapeutics, Vigene Biosciences, Virovek, and Wuxi Advanced Therapies.

Answer : The driving factors of the U.S. viral vectors and plasmid DNA manufacturing market are the increasing gene therapy commercialization, expanding clinical trial activity, and rising investments in advanced biomanufacturing infrastructure.